EXPAREL bupivacaine liposome injectable suspension Updated Nov 13
EXPAREL is a mature, approved product with no upcoming binary drug catalyst. The stock trades at the $36.50 Viatris acquisition price, so the near-term move depends entirely on deal closing (expected by end of 2026). Watch for the Ninth Circuit royalty ruling's impact on EXPAREL margins and any updates on the tender offer's regulatory clearance.
- NOPAIN Act tailwind: Federal separate reimbursement for non-opioid pain management in outpatient settings creates a structural growth driver for EXPAREL.
- Patent protection through 2030: Settlements with Fresenius, Jiangsu Hengrui, and eVenus (April 2025) pushed generic entry to 2030, extending the product's exclusivity runway.
- Expanding label: FDA approved two additional nerve block indications in November 2023, broadening the addressable market.
- Generic competition: FDA approved Jiangsu Hengrui's generic bupivacaine liposome in July 2024, and while patent settlements push entry to 2030, further legal challenges could emerge.
- Royalty dispute: On November 6, 2026, the Ninth Circuit reversed part of the lower court ruling, holding that Pacira owes royalties on EXPAREL made using its 200-liter process. This could pressure gross margins and put a $28.3M cash payment from RDF at risk.
- Revenue erosion: Q3 2026 EXPAREL revenue was $176.65M, slightly down from $179M a year earlier, suggesting growth may be plateauing.